EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment Efficacy of a Dual Release of Aflibercept and Dexamethasone From a Single Hydrogel Drug Delivery System in a Rodent Model

Kayla M Rudeen, Chryssa M Maloney, Katherine L Lydon, Leandro B C Teixeria, William F Mieler, Jennifer J Kang-Mieler

Translational Vision Science & Technology · 2025

DOI: 10.1167/tvst.14.6.31 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Vision Science & Technology, 2025. Verfasst von Kayla M Rudeen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Dexamethasone, Recombinant Fusion Proteins, Choroidal Neovascularization. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Age-related macular degeneration (AMD) is the leading cause of vision loss for the elderly population. Wet AMD, which accounts for approximately 15% of AMD cases, is characterized by abnormal blood vessel growth from the choroid into the subretinal space. Although intravitreal anti-vascular endothelial growth factor (VEGF) agents have become the standard of care for wet AMD, there is a growing subset of patients who do not fully respond to monotherapy anti-VEGF treatment. In previously published reports, corticosteroids have shown improvements in treatment efficacy when administered with anti-VEGF in a subset of non-responders to anti-VEGF monotherapy.

Methods

A combination dexamethasone and aflibercept drug delivery system (Combo-DDS) was evaluated in a laser-induced rodent model of choroidal neovascularization (CNV). Longitudinal monitoring was done through week 22 using fluorescein angiography (FA) and spectral domain optical coherence tomography (SD-OCT). Multi-Otsu thresholding was used to quantify the lesion area based on late-phase FA images. In addition, preliminary safety and biocompatibility of the Combo-DDS were evaluated by intraocular pressure (IOP) measurements, electroretinogram (ERG), and histology (n = 6 eyes/group).

Results

In the laser-induced CNV model, CNV lesions (n = 28-36 lesions/group) were monitored longitudinally. Combo-DDS showed a regression in lesion size starting at week 2 that continued through the end of study. IOP, ERG, and histology showed preliminary safety and biocompatibility of the Combo-DDS.

Conclusions

This study demonstrated that Combo-DDS maintained treatment efficacy in a laser-induced CNV rodent model for 6 months. Translational Relevance: The Combo-DDS shows the potential to eliminate the need for separate dosing regiments of anti-VEGF and corticosteroids for non-responders to anti-VEGF monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Vascular Endothelial Growth FactorDexamethasoneRecombinant Fusion ProteinsChoroidal NeovascularizationDrug Delivery SystemsAngiogenesis InhibitorsAnimalsDisease Models, AnimalTomography, Optical CoherenceFluorescein AngiographyRatsHydrogelsIntravitreal InjectionsElectroretinographyIntraocular PressureMaleTreatment Outcome

Substanzen

afliberceptReceptors, Vascular Endothelial Growth FactorDexamethasoneRecombinant Fusion ProteinsHydrogelsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL, USA.
  • Local Delivery Translational Sciences, AbbVie, North Chicago, IL, USA.
  • Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois, Chicago, IL, USA.
  • Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, USA.

Förderung

  • NEI NIH HHS

Zitieren

APA

Rudeen, K. M., Maloney, C. M., Lydon, K. L., Teixeria, L. B. C., Mieler, W. F., & Kang-Mieler, J. J. (2025). Treatment Efficacy of a Dual Release of Aflibercept and Dexamethasone From a Single Hydrogel Drug Delivery System in a Rodent Model. Translational Vision Science & Technology. https://doi.org/10.1167/tvst.14.6.31

Vancouver

Rudeen KM, Maloney CM, Lydon KL, Teixeria LBC, Mieler WF, Kang-Mieler JJ. Treatment Efficacy of a Dual Release of Aflibercept and Dexamethasone From a Single Hydrogel Drug Delivery System in a Rodent Model. Translational Vision Science & Technology. 2025. doi:10.1167/tvst.14.6.31

BibTeX
@article{Rudeen2025,
  author = {Rudeen, Kayla M and Maloney, Chryssa M and Lydon, Katherine L and Teixeria, Leandro B C and Mieler, William F and Kang-Mieler, Jennifer J},
  title = {Treatment Efficacy of a Dual Release of Aflibercept and Dexamethasone From a Single Hydrogel Drug Delivery System in a Rodent Model},
  journal = {Translational Vision Science & Technology},
  year = {2025},
  doi = {10.1167/tvst.14.6.31}
}
Kostenlos starten →